JP6787995B2 - 細胞毒性ベンゾジアゼピン誘導体の調製方法 - Google Patents
細胞毒性ベンゾジアゼピン誘導体の調製方法 Download PDFInfo
- Publication number
- JP6787995B2 JP6787995B2 JP2018502791A JP2018502791A JP6787995B2 JP 6787995 B2 JP6787995 B2 JP 6787995B2 JP 2018502791 A JP2018502791 A JP 2018502791A JP 2018502791 A JP2018502791 A JP 2018502791A JP 6787995 B2 JP6787995 B2 JP 6787995B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- salt
- reagent
- reacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[C@@](C(N[C@@](C)C(Nc1cc(CO)cc(COP)c1)=O)=O)NC(CCCCC(*)=O)=O Chemical compound C[C@@](C(N[C@@](C)C(Nc1cc(CO)cc(COP)c1)=O)=O)NC(CCCCC(*)=O)=O 0.000 description 47
- ROVBYDCETXMZLN-NSHDSACASA-N COc(c(O)c1)cc2c1N=C[C@H](Cc1ccccc11)N1C2=O Chemical compound COc(c(O)c1)cc2c1N=C[C@H](Cc1ccccc11)N1C2=O ROVBYDCETXMZLN-NSHDSACASA-N 0.000 description 7
- CDNFJWMYFUTPRD-KYJUHHDHSA-N COc(cc(c(NC[C@H](C1)N2c3c1cccc3)c1)C2=O)c1OCc1cc([N+]([O-])=O)cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)c1 Chemical compound COc(cc(c(NC[C@H](C1)N2c3c1cccc3)c1)C2=O)c1OCc1cc([N+]([O-])=O)cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)c1 CDNFJWMYFUTPRD-KYJUHHDHSA-N 0.000 description 2
- GNTXGZAHEBHSKY-UHFFFAOYSA-N CCOCc1cc([N+]([O-])=O)cc(COc(cc(c(C(N(CC2)C3=C2C=CCC3)=O)c2)N=C)c2OC)c1 Chemical compound CCOCc1cc([N+]([O-])=O)cc(COc(cc(c(C(N(CC2)C3=C2C=CCC3)=O)c2)N=C)c2OC)c1 GNTXGZAHEBHSKY-UHFFFAOYSA-N 0.000 description 1
- XOCJBGONEJWIDQ-IBGZPJMESA-N COc(c(OCc1cc(COI)cc([N+]([O-])=O)c1)c1)cc2c1NC[C@H](Cc1c3cccc1)N3C2=O Chemical compound COc(c(OCc1cc(COI)cc([N+]([O-])=O)c1)c1)cc2c1NC[C@H](Cc1c3cccc1)N3C2=O XOCJBGONEJWIDQ-IBGZPJMESA-N 0.000 description 1
- DEXQJGYKHCNXLU-UHFFFAOYSA-N COc(cc(C(N(CC1)C2=C1C=CCC2)=O)c(N=C)c1)c1OCc1cc([N+]([O-])=O)cc(CI)c1 Chemical compound COc(cc(C(N(CC1)C2=C1C=CCC2)=O)c(N=C)c1)c1OCc1cc([N+]([O-])=O)cc(CI)c1 DEXQJGYKHCNXLU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195023P | 2015-07-21 | 2015-07-21 | |
| US62/195,023 | 2015-07-21 | ||
| US201662327973P | 2016-04-26 | 2016-04-26 | |
| US62/327,973 | 2016-04-26 | ||
| PCT/US2016/043406 WO2017015496A1 (en) | 2015-07-21 | 2016-07-21 | Methods of preparing cytotoxic benzodiazepine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180147A Division JP6995178B2 (ja) | 2015-07-21 | 2020-10-28 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526340A JP2018526340A (ja) | 2018-09-13 |
| JP2018526340A5 JP2018526340A5 (enExample) | 2019-08-29 |
| JP6787995B2 true JP6787995B2 (ja) | 2020-11-18 |
Family
ID=56557925
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502791A Expired - Fee Related JP6787995B2 (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2018502800A Withdrawn JP2018522018A (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2018502785A Expired - Fee Related JP6858745B2 (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2020180147A Expired - Fee Related JP6995178B2 (ja) | 2015-07-21 | 2020-10-28 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2021049502A Active JP7337114B2 (ja) | 2015-07-21 | 2021-03-24 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2021202215A Active JP7334228B2 (ja) | 2015-07-21 | 2021-12-14 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2023132536A Withdrawn JP2023162264A (ja) | 2015-07-21 | 2023-08-16 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2023134420A Withdrawn JP2023166434A (ja) | 2015-07-21 | 2023-08-22 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502800A Withdrawn JP2018522018A (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2018502785A Expired - Fee Related JP6858745B2 (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2020180147A Expired - Fee Related JP6995178B2 (ja) | 2015-07-21 | 2020-10-28 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2021049502A Active JP7337114B2 (ja) | 2015-07-21 | 2021-03-24 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2021202215A Active JP7334228B2 (ja) | 2015-07-21 | 2021-12-14 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2023132536A Withdrawn JP2023162264A (ja) | 2015-07-21 | 2023-08-16 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2023134420A Withdrawn JP2023166434A (ja) | 2015-07-21 | 2023-08-22 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (11) | US9890179B2 (enExample) |
| EP (7) | EP4163284A1 (enExample) |
| JP (8) | JP6787995B2 (enExample) |
| KR (5) | KR102660070B1 (enExample) |
| CN (5) | CN113087763A (enExample) |
| AU (7) | AU2016297607A1 (enExample) |
| CA (4) | CA2992082A1 (enExample) |
| CY (2) | CY1122553T1 (enExample) |
| DK (2) | DK3325483T3 (enExample) |
| ES (4) | ES2820358T3 (enExample) |
| HK (1) | HK1252322A1 (enExample) |
| HR (1) | HRP20201479T1 (enExample) |
| HU (1) | HUE051541T2 (enExample) |
| IL (10) | IL294651B2 (enExample) |
| LT (2) | LT3325482T (enExample) |
| PL (2) | PL3325483T3 (enExample) |
| PT (2) | PT3325483T (enExample) |
| RS (2) | RS59806B1 (enExample) |
| RU (3) | RU2727151C2 (enExample) |
| SG (2) | SG10202106529XA (enExample) |
| SI (2) | SI3325482T1 (enExample) |
| SM (2) | SMT202000506T1 (enExample) |
| WO (3) | WO2017015502A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018524387A (ja) * | 2015-07-21 | 2018-08-30 | イミュノジェン・インコーポレーテッド | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118098938A (zh) | 2016-03-22 | 2024-05-28 | Ev 集团 E·索尔纳有限责任公司 | 用于衬底的接合的装置和方法 |
| WO2018075692A2 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| EP3559039A1 (en) | 2016-12-22 | 2019-10-30 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| RU2762891C2 (ru) | 2017-01-25 | 2021-12-23 | Иммуноджен, Инк. | Способы получения цитотоксических производных бензодиазепина |
| CN120795120A (zh) | 2018-06-05 | 2025-10-17 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| EP3880656B1 (en) * | 2018-11-12 | 2024-03-20 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| EP3880681B1 (en) * | 2018-11-12 | 2024-03-13 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| KR20220010481A (ko) * | 2019-03-29 | 2022-01-25 | 이뮤노젠 아이엔씨 | 비정상 세포 성장의 억제 또는 증식성 질환의 치료를 위한 세포독성 비스-벤조디아제핀 유도체 및 세포결합제와 이의 접합체 |
| CN119486758A (zh) | 2022-06-30 | 2025-02-18 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3763183A (en) | 1972-07-10 | 1973-10-02 | Sterling Drug Inc | 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines |
| US3860600A (en) | 1972-07-10 | 1975-01-14 | Sterling Drug Inc | Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines |
| US4678784A (en) | 1984-04-11 | 1987-07-07 | Mcneilab, Inc. | Method for the treatment of LHRH diseases and conditions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| ES2244210T3 (es) | 1998-08-27 | 2005-12-01 | Spirogen Limited | Pirrolobenzodiazepinas. |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| DE60032633T2 (de) | 1999-11-24 | 2007-10-04 | Immunogen Inc., Cambridge | Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung |
| US6548042B2 (en) * | 2000-08-07 | 2003-04-15 | Arstad Erik | Bis-phosphonate compounds |
| UA75093C2 (en) * | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| WO2004013093A2 (en) | 2002-08-02 | 2004-02-12 | Immunogen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| ES2361739T3 (es) | 2002-08-16 | 2011-06-21 | Immunogen, Inc. | Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña. |
| RU2338747C2 (ru) | 2003-03-31 | 2008-11-20 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| AU2003215810B2 (en) | 2003-03-31 | 2009-06-18 | Council Of Scientific And Industrial Research | Pyrrolo((2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof |
| US6884799B2 (en) | 2003-03-31 | 2005-04-26 | Council Of Scientific And Industrial Research | Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof |
| RU2314309C2 (ru) | 2003-03-31 | 2008-01-10 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| CA2543318C (en) | 2003-10-22 | 2013-01-08 | B. Rao Vishnuvajjala | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| WO2005063759A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific And Industrial Research | PROCESS FOR PREPARING PYRROLO[2, 1-c] [1, 4] BENZODIAZEPINE HYBRIDS |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| PT2270010E (pt) * | 2004-03-01 | 2012-03-12 | Spirogen Ltd | Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2 |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| GB0412492D0 (en) * | 2004-06-04 | 2004-07-07 | Sterix Ltd | Compound |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US7612062B2 (en) | 2005-04-21 | 2009-11-03 | Spirogen Limited | Pyrrolobenzodiazepines |
| ATE427949T1 (de) | 2005-10-05 | 2009-04-15 | Spirogen Ltd | 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
| ATE475660T1 (de) * | 2005-12-21 | 2010-08-15 | Abbott Lab | Antivirale verbindungen |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| DE112007000079B4 (de) | 2006-02-13 | 2015-08-13 | Council Of Scientific & Industrial Research | Neuartige Bis-Pyrrolo[2,1-c][1,4]benzodiazepin-anthrachinon Konjugate und ein Verfahren zu deren Herstellung |
| PT2032606E (pt) | 2006-05-30 | 2014-02-05 | Genentech Inc | Anticorpos e imunoconjugados e respetivas utilizações |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| ATE543826T1 (de) | 2007-08-01 | 2012-02-15 | Council Scient Ind Res | Als selektive antitumormittel geeignete pyrroloä2,1-cüä1,4übenzodiazepinglycosid-prodru s |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| KR101892411B1 (ko) | 2008-04-30 | 2018-08-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0822260D0 (en) * | 2008-12-05 | 2009-01-14 | Merten Christoph | Assay |
| EP2383263B1 (en) * | 2008-12-30 | 2014-04-16 | Industry-academic Cooperation Foundation, Chosun University | Novel thiazolidinedione derivative and use thereof |
| IL271761B (en) | 2009-02-05 | 2022-09-01 | Immunogen Inc | (12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepin-6-one, 4-benzyloxy-5-methoxy-2-nitrobenzoic acid and processes for preparing the same |
| KR20120080611A (ko) | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| WO2011071078A1 (ja) * | 2009-12-08 | 2011-06-16 | 国立大学法人岐阜大学 | 芳香族化合物、並びに、それを用いたオリゴヌクレオチド誘導体合成用修飾担体、オリゴヌクレオチド誘導体及びオリゴヌクレオチド構築物 |
| US8962279B2 (en) * | 2009-12-30 | 2015-02-24 | Intel Corporation | Solid-phase chelators and electronic biosensors |
| TR201903027T4 (tr) * | 2010-02-11 | 2019-03-21 | Celgene Corp | Arilmetoksi izoindolin türevleri ve bunları içeren kompozisyonlar ve bunları kullanma yöntemleri. |
| EP3196212B1 (en) | 2010-02-24 | 2020-06-03 | ImmunoGen, Inc. | Immunoconjugates comprising a folate receptor 1 antibody |
| MX2012011900A (es) | 2010-04-15 | 2013-03-21 | Seattle Genetics Inc | Conjugados de pirrolobenzodiazepina diana. |
| EP2558475A1 (en) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
| NZ602241A (en) | 2010-04-15 | 2015-03-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| CN113896731A (zh) * | 2011-02-15 | 2022-01-07 | 伊缪诺金公司 | 细胞毒性苯并二氮杂䓬衍生物 |
| CN102234253B (zh) * | 2011-06-02 | 2013-07-03 | 重庆莱美药业股份有限公司 | 一种制备非布索坦中间体的方法 |
| EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| WO2015051045A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE |
| CN104628772A (zh) * | 2013-11-07 | 2015-05-20 | 四川恒康发展有限责任公司 | 一种抗肿瘤前药及其激活剂、组合物和应用 |
| CN103664896B (zh) * | 2013-11-25 | 2016-03-02 | 济南精合医药科技有限公司 | 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法 |
| PL3189056T3 (pl) | 2014-09-03 | 2020-11-02 | Immunogen, Inc. | Cytotoksyczne pochodne benzodiazepinowe |
| US9381256B2 (en) | 2014-09-03 | 2016-07-05 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| TW201609152A (zh) * | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
| IL294651B2 (en) * | 2015-07-21 | 2024-02-01 | Immunogen Inc | Methods for the preparation of cytotoxic benzodiazepine compounds |
| PT3380525T (pt) * | 2015-11-25 | 2024-02-05 | Immunogen Inc | Formulações farmacêuticas e métodos que as utilizam |
-
2016
- 2016-07-21 IL IL294651A patent/IL294651B2/en unknown
- 2016-07-21 RS RS20191647A patent/RS59806B1/sr unknown
- 2016-07-21 IL IL283355A patent/IL283355B/en unknown
- 2016-07-21 ES ES16745598T patent/ES2820358T3/es active Active
- 2016-07-21 CN CN202110366892.7A patent/CN113087763A/zh active Pending
- 2016-07-21 KR KR1020187005041A patent/KR102660070B1/ko active Active
- 2016-07-21 CA CA2992082A patent/CA2992082A1/en active Pending
- 2016-07-21 CN CN201680051138.1A patent/CN108290895B/zh not_active Expired - Fee Related
- 2016-07-21 SG SG10202106529XA patent/SG10202106529XA/en unknown
- 2016-07-21 IL IL305989A patent/IL305989A/en unknown
- 2016-07-21 KR KR1020247012991A patent/KR20240055903A/ko not_active Withdrawn
- 2016-07-21 US US15/216,517 patent/US9890179B2/en not_active Expired - Fee Related
- 2016-07-21 JP JP2018502791A patent/JP6787995B2/ja not_active Expired - Fee Related
- 2016-07-21 SM SM20200506T patent/SMT202000506T1/it unknown
- 2016-07-21 EP EP22195446.4A patent/EP4163284A1/en not_active Withdrawn
- 2016-07-21 US US15/216,548 patent/US10081640B2/en active Active
- 2016-07-21 EP EP16748205.8A patent/EP3325485B1/en active Active
- 2016-07-21 PL PL16745961T patent/PL3325483T3/pl unknown
- 2016-07-21 PT PT167459619T patent/PT3325483T/pt unknown
- 2016-07-21 DK DK16745961.9T patent/DK3325483T3/da active
- 2016-07-21 JP JP2018502800A patent/JP2018522018A/ja not_active Withdrawn
- 2016-07-21 CN CN201680053093.1A patent/CN108026103B/zh not_active Expired - Fee Related
- 2016-07-21 HR HRP20201479TT patent/HRP20201479T1/hr unknown
- 2016-07-21 HU HUE16745598A patent/HUE051541T2/hu unknown
- 2016-07-21 ES ES19200626T patent/ES2933376T3/es active Active
- 2016-07-21 EP EP16745961.9A patent/EP3325483B1/en active Active
- 2016-07-21 WO PCT/US2016/043414 patent/WO2017015502A1/en not_active Ceased
- 2016-07-21 CN CN202110219412.4A patent/CN113004288A/zh active Pending
- 2016-07-21 WO PCT/US2016/043406 patent/WO2017015496A1/en not_active Ceased
- 2016-07-21 ES ES16745961T patent/ES2764548T3/es active Active
- 2016-07-21 LT LTEP16745598.9T patent/LT3325482T/lt unknown
- 2016-07-21 IL IL286788A patent/IL286788B2/en unknown
- 2016-07-21 IL IL305279A patent/IL305279A/en unknown
- 2016-07-21 AU AU2016297607A patent/AU2016297607A1/en not_active Abandoned
- 2016-07-21 HK HK18111602.7A patent/HK1252322A1/zh unknown
- 2016-07-21 PT PT167455989T patent/PT3325482T/pt unknown
- 2016-07-21 AU AU2016297087A patent/AU2016297087B2/en not_active Ceased
- 2016-07-21 PL PL16745598T patent/PL3325482T3/pl unknown
- 2016-07-21 KR KR1020247012816A patent/KR20240055894A/ko not_active Withdrawn
- 2016-07-21 SM SM20200004T patent/SMT202000004T1/it unknown
- 2016-07-21 EP EP19200626.0A patent/EP3653628B1/en active Active
- 2016-07-21 EP EP20181645.1A patent/EP3778602B1/en active Active
- 2016-07-21 CA CA3227588A patent/CA3227588A1/en active Pending
- 2016-07-21 RU RU2018105756A patent/RU2727151C2/ru active
- 2016-07-21 EP EP16745598.9A patent/EP3325482B1/en active Active
- 2016-07-21 CA CA2991326A patent/CA2991326A1/en not_active Abandoned
- 2016-07-21 LT LTEP16745961.9T patent/LT3325483T/lt unknown
- 2016-07-21 SI SI201630923T patent/SI3325482T1/sl unknown
- 2016-07-21 KR KR1020187003181A patent/KR102659706B1/ko active Active
- 2016-07-21 EP EP23183947.3A patent/EP4286387A3/en not_active Withdrawn
- 2016-07-21 SG SG10202009354SA patent/SG10202009354SA/en unknown
- 2016-07-21 KR KR1020187005040A patent/KR20180038460A/ko not_active Withdrawn
- 2016-07-21 WO PCT/US2016/043402 patent/WO2017015495A1/en not_active Ceased
- 2016-07-21 CA CA2991305A patent/CA2991305C/en active Active
- 2016-07-21 CN CN201680053120.5A patent/CN108055844A/zh active Pending
- 2016-07-21 JP JP2018502785A patent/JP6858745B2/ja not_active Expired - Fee Related
- 2016-07-21 AU AU2016297608A patent/AU2016297608B2/en not_active Ceased
- 2016-07-21 RU RU2018105752A patent/RU2018105752A/ru not_active Application Discontinuation
- 2016-07-21 SI SI201630578T patent/SI3325483T1/sl unknown
- 2016-07-21 ES ES20181645T patent/ES2959741T3/es active Active
- 2016-07-21 RU RU2018105609A patent/RU2746322C2/ru active
- 2016-07-21 US US15/216,512 patent/US9873708B2/en active Active
- 2016-07-21 DK DK16745598.9T patent/DK3325482T3/da active
- 2016-07-21 RS RS20201132A patent/RS60840B1/sr unknown
-
2017
- 2017-12-11 US US15/837,832 patent/US10370389B2/en active Active
-
2018
- 2018-01-03 US US15/860,864 patent/US10392407B2/en not_active Expired - Fee Related
- 2018-01-11 IL IL256860A patent/IL256860B/en active IP Right Grant
- 2018-01-11 IL IL256854A patent/IL256854A/en unknown
- 2018-01-11 IL IL256861A patent/IL256861B/en active IP Right Grant
- 2018-09-12 US US16/129,008 patent/US10899775B2/en active Active
-
2019
- 2019-06-06 US US16/433,117 patent/US10787463B2/en active Active
- 2019-06-21 US US16/448,261 patent/US20200017526A1/en not_active Abandoned
- 2019-12-30 CY CY20191101364T patent/CY1122553T1/el unknown
-
2020
- 2020-08-10 IL IL276631A patent/IL276631B/en unknown
- 2020-08-10 IL IL276630A patent/IL276630B/en active IP Right Grant
- 2020-08-12 US US16/991,700 patent/US11420982B2/en active Active
- 2020-09-23 CY CY20201100899T patent/CY1123390T1/el unknown
- 2020-10-28 JP JP2020180147A patent/JP6995178B2/ja not_active Expired - Fee Related
- 2020-11-23 US US17/101,942 patent/US20210171547A1/en not_active Abandoned
-
2021
- 2021-03-24 JP JP2021049502A patent/JP7337114B2/ja active Active
- 2021-04-20 AU AU2021202403A patent/AU2021202403B2/en not_active Ceased
- 2021-05-17 AU AU2021203148A patent/AU2021203148B2/en not_active Ceased
- 2021-12-14 JP JP2021202215A patent/JP7334228B2/ja active Active
-
2022
- 2022-12-14 US US18/080,973 patent/US20230257400A1/en not_active Abandoned
-
2023
- 2023-03-03 AU AU2023201339A patent/AU2023201339A1/en not_active Abandoned
- 2023-04-11 AU AU2023202221A patent/AU2023202221A1/en not_active Abandoned
- 2023-08-16 JP JP2023132536A patent/JP2023162264A/ja not_active Withdrawn
- 2023-08-22 JP JP2023134420A patent/JP2023166434A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018524387A (ja) * | 2015-07-21 | 2018-08-30 | イミュノジェン・インコーポレーテッド | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6995178B2 (ja) | 細胞毒性ベンゾジアゼピン誘導体の調製方法 | |
| HK40088821A (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| HK40029973A (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| HK40029973B (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| HK1252323B (en) | Methods of preparing cytotoxic benzodiazepine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190719 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190719 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200615 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200915 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201002 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201029 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6787995 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |